Immunovant, Inc. financial data

Symbol
IMVT on Nasdaq
Location
Durham, NC
Fiscal year end
31 March
Latest financial report
10-Q - Q4 2025 - 06 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1209% % 27%
Debt-to-equity 8.9% % -24%
Return On Equity -66% % 16%
Return On Assets -60% % 13%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 203,532,180 shares 20%
Common Stock, Shares, Outstanding 203,316,885 shares 38%
Entity Public Float $1,866,600,000 USD -14%
Common Stock, Value, Issued $20,000 USD 43%
Weighted Average Number of Shares Outstanding, Basic 181,513,386 shares 24%
Weighted Average Number of Shares Outstanding, Diluted 181,513,386 shares 24%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense $79,149,000 USD 10%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $460,556,000 USD -21%
Income Tax Expense (Benefit) $3,643,000 USD 576%
Net Income (Loss) Attributable to Parent $464,199,000 USD -21%
Earnings Per Share, Basic -2.68 USD/shares -3.1%
Earnings Per Share, Diluted -2.68 USD/shares -3.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $994,525,000 USD 165%
Accounts Receivable, after Allowance for Credit Loss, Current $1,643,000 USD -26%
Assets, Current $1,042,939,000 USD 153%
Property, Plant and Equipment, Net $531,000 USD -29%
Operating Lease, Right-of-Use Asset $98,000 USD -26%
Other Assets, Noncurrent $8,922,000 USD 17%
Assets $1,052,392,000 USD 150%
Accounts Payable, Current $8,616,000 USD -57%
Accrued Liabilities, Current $50,748,000 USD 23%
Liabilities, Current $66,257,000 USD -3%
Operating Lease, Liability, Noncurrent $0 USD -100%
Liabilities $66,257,000 USD -3%
Accumulated Other Comprehensive Income (Loss), Net of Tax $1,197,000 USD -52%
Retained Earnings (Accumulated Deficit) $1,597,273,000 USD -41%
Stockholders' Equity Attributable to Parent $986,135,000 USD 180%
Liabilities and Equity $1,052,392,000 USD 150%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $117,411,000 USD -54%
Net Cash Provided by (Used in) Financing Activities $2,918,000 USD 325%
Net Cash Provided by (Used in) Investing Activities $0 USD
Common Stock, Shares Authorized 500,000,000 shares 0%
Common Stock, Shares, Issued 203,316,885 shares 38%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $115,059,000 USD -53%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $994,525,000 USD 165%
Deferred Tax Assets, Valuation Allowance $218,753,000 USD 55%
Deferred Tax Assets, Gross $219,851,000 USD 55%
Operating Lease, Liability $138,000 USD -89%
Depreciation $107,000 USD 34%
Payments to Acquire Property, Plant, and Equipment $0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $465,481,000 USD -22%
Lessee, Operating Lease, Liability, to be Paid $141,000 USD -89%
Operating Lease, Liability, Current $98,000 USD -29%
Lessee, Operating Lease, Liability, to be Paid, Year One $141,000 USD -88%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $3,000 USD -88%
Deferred Tax Assets, Operating Loss Carryforwards $153,370,000 USD 56%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,010,000 shares
Additional Paid in Capital $2,582,191,000 USD 74%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $1,098,000 USD 216%
Share-based Payment Arrangement, Expense $55,800,000 USD 18%
Preferred Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%